306 related articles for article (PubMed ID: 29034790)
1. Minimal toxicity after proton beam therapy for prostate and pelvic nodal irradiation: results from the proton collaborative group REG001-09 trial.
Chuong MD; Hartsell W; Larson G; Tsai H; Laramore GE; Rossi CJ; Wilkinson JB; Kaiser A; Vargas C
Acta Oncol; 2018 Mar; 57(3):368-374. PubMed ID: 29034790
[TBL] [Abstract][Full Text] [Related]
2. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N
Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899
[TBL] [Abstract][Full Text] [Related]
3. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
[TBL] [Abstract][Full Text] [Related]
4. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
5. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
[TBL] [Abstract][Full Text] [Related]
6. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
7. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
8. Probability of normal tissue complications for hematologic and gastrointestinal toxicity in postoperative whole pelvic radiotherapy for gynecologic malignancies using intensity-modulated proton therapy with robust optimization.
Yoshimura T; Yamada R; Kinoshita R; Matsuura T; Kanehira T; Tamura H; Nishioka K; Yasuda K; Taguchi H; Katoh N; Kobashi K; Hashimoto T; Aoyama H
J Radiat Res; 2024 May; 65(3):369-378. PubMed ID: 38499489
[TBL] [Abstract][Full Text] [Related]
9. Extreme hypofractionated proton radiotherapy for prostate cancer using pencil beam scanning: Dosimetry, acute toxicity and preliminary results.
Kubeš J; Vondráček V; Andrlik M; Navrátil M; Sláviková S; Vítek P; Rosina J; Abrahámová J; Prausová J; Grebenyuk A; Dědečková K
J Med Imaging Radiat Oncol; 2019 Dec; 63(6):829-835. PubMed ID: 31486267
[TBL] [Abstract][Full Text] [Related]
10. Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting.
Santos PMG; Barsky AR; Hwang WT; Deville C; Wang X; Both S; Bekelman JE; Christodouleas JP; Vapiwala N
Cancer; 2019 Dec; 125(23):4278-4293. PubMed ID: 31503338
[TBL] [Abstract][Full Text] [Related]
11. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus.
Kalakota K; Liauw SL
Urology; 2013 Jun; 81(6):1196-201. PubMed ID: 23540863
[TBL] [Abstract][Full Text] [Related]
12. Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis.
Dutz A; Agolli L; Baumann M; Troost EGC; Krause M; Hölscher T; Löck S
Acta Oncol; 2019 Jun; 58(6):916-925. PubMed ID: 30882264
[No Abstract] [Full Text] [Related]
13. Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy.
Deville C; Jain A; Hwang WT; Woodhouse KD; Both S; Wang S; Gabriel PE; Christodouleas JP; Bekelman J; Tochner Z; Vapiwala N
Acta Oncol; 2018 Nov; 57(11):1506-1514. PubMed ID: 30028227
[TBL] [Abstract][Full Text] [Related]
14. Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.
Matta R; Chapple CR; Fisch M; Heidenreich A; Herschorn S; Kodama RT; Koontz BF; Murphy DG; Nguyen PL; Nam RK
Eur Urol; 2019 Mar; 75(3):464-476. PubMed ID: 30573316
[TBL] [Abstract][Full Text] [Related]
15. Pelvic Lymph Node Irradiation Including Pararectal Sentinel Nodes for Prostate Cancer Patients: Treatment Optimization Comparing Intensity Modulated X-rays, Volumetric Modulated Arc Therapy, and Intensity Modulated Proton Therapy.
Vees H; Dipasquale G; Nouet P; Zilli T; Cozzi L; Miralbell R
Technol Cancer Res Treat; 2015 Apr; 14(2):181-9. PubMed ID: 24694113
[TBL] [Abstract][Full Text] [Related]
16. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
17. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
[TBL] [Abstract][Full Text] [Related]
18. Late toxicity rates following definitive radiotherapy for prostate cancer.
Ohri N; Dicker AP; Showalter TN
Can J Urol; 2012 Aug; 19(4):6373-80. PubMed ID: 22892261
[TBL] [Abstract][Full Text] [Related]
19. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
[TBL] [Abstract][Full Text] [Related]
20. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.
Habl G; Katayama S; Uhl M; Kessel KA; Edler L; Debus J; Herfarth K; Sterzing F
BMC Cancer; 2015 Nov; 15():868. PubMed ID: 26547188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
